METVIXIA

Opinions on drugs - Posted on Apr 15 2014

Reason for request

Renewal of inclusion

Clinical Benefit

Substantial	Superficial, non-recurrent basal cell carcinoma of the trunk, limbs and neck : substantial AB in inoperable patients with extensive or multiple lesions or lesions that are difficult to access surgically. Non-pigmented squamous cell carcinoma in situ (Bowen’s disease) in immunocompetent subjects when surgery is not possible: substantial AB.
Moderate	Multiple, thin or non-hyperkeratotic and non-pigmented actinic keratoses of the scalp : moderate AB. Superficial, non-recurrent basal cell carcinoma of the trunk, limbs and neck : moderate AB in other cases

Clinical Added Value

minor

In superficial, non-recurrent basal cell carcinoma of the trunk, limbs and neck, METVIXIA :

- provides a minor improvement in actual benefit (level IV) in inoperable patients with extensive or multiple lesions or lesions that are difficult to access surgically ;

- does not provide any improvement in actual benefit (level V) in other cases.

METVIXIA provides a minor improvement in actual benefit (level IV) in the treatment of non-pigmented squamous cell carcinoma in situ (Bowen’s disease) in immunocompetent subjects when surgery is not possible.

no clinical added value

The improvement in actual benefit provided by METVIXIA is unchanged (level V, non-existent) in the treatment of thin or non-hyperkeratotic and non-pigmented actinic keratoses of the face and scalp.